|« Previous month||Next month »|
30-Oct-2014 - India has relaxed stability data requirements for API manufacturers seeking “written confirmation of quality” certificates needed to ship to the EU.
30-Oct-2014 - Animal astronauts on the International Space Station will test an implant which allows doctors back on earth to deliver drugs by remote control.
30-Oct-2014 - Hardly anybody downloads Big Pharma apps according to a new report that suggests drugmakers seeking greater mHealth engagement should ditch the product-focused model and seek expert help.
30-Oct-2014 - Novo Nordisk on Wednesday announced plans to hire up to 90 people at its newly-acquired manufacturing facility in West Lebanon, New Hampshire.
29-Oct-2014 - India will ban PET packaging for liquid drug formulations for children, the elderly and women of reproductive age in November according to a Government statement.
29-Oct-2014 - So it appears the future of Sanofi’s CEO Christopher Viehbacher was on the agenda after all.
29-Oct-2014 - A head-hunter explains why Regeneron, Novo Nordisk and Genentech top a global survey of science employers, but Pfizer is nowhere to be seen in the top 20.
29-Oct-2014 - The European Directorate for the Quality of Medicines & Health Care, under the European Pharmacopeia, has set a new policy for the testing of bacterial endotoxins.
28-Oct-2014 - A plant being set up by Pharma Action and meat supplier Toennies will produce 15 tonnes of 100% traceable crude heparin a year.
28-Oct-2014 - Psychiatric drugs should be renamed according to their chemical make-up, not the symptoms they treat, according to leading neuropsychopharmacologists.
28-Oct-2014 - Jordanian drugmaker Hikma says it has received a US FDA (Food and Drug Administration) Warning Letter over environmental monitoring at its plant in Portugal.
27-Oct-2014 - Former employees of Procter & Gamble, Merck & Co. and Bristol Myers Squibb have all found new homes in the pharma industry in this week's People column.
27-Oct-2014 - Roche has announced plans to invest 3bn Swiss Francs ($3.2bn) in a 433-ft R&D centre and extra offices for 3,600 employees.
27-Oct-2014 - A superbug-fuelled resurgence of polymyxin antibiotics has prompted the European Medicines Agency (EMA) to re-examine safety warnings for the side effect heavy anti-infectives
27-Oct-2014 - Novo Nordisk has been served with a subpoena over alleged manufacturing issues at its site in Kalundborg, Denmark.
27-Oct-2014 - What may seem to be relatively minor changes between the FDA’s draft and final guidance on delaying, denying, limiting or refusing a facility inspection could actually be more major as...
23-Oct-2014 - Drugmakers’ clashes with regulators over the suitability of API starting materials suggest ICH Q11 is open to interpretation and that clarification is needed according to the EMA.
23-Oct-2014 - GlaxoSmithKline plans to cut manufacturing, sales and R&D as part of a three year plan to save £1bn ($1.6bn) annually.
23-Oct-2014 - Ebola vaccine developers can seek scientific guidance and approval through a rolling assessment system established by EMA to accelerate the process review.
23-Oct-2014 - Almost 100 jobs at a commercial packaging facility in New York are set to go as part of Actavis’s continued integration of Forest Laboratories.
22-Oct-2014 - A seasonal flu vaccine taken in the form of an oral solid dose has been found comparable to currently available jabs, according to data presented by developer Vaxart.
22-Oct-2014 - DG Health will keep responsibility for the EMA according to European Commission President-elect Jean-Claude Juncker, who confirmed plans to hand the agency to DG Enterprise have been abandoned.
22-Oct-2014 - Janssen-Cilag’s bedaquiline and Otsuka’s delamanid notwithstanding, the drug industry is not spending enough on the development of tuberculosis medicines according to the WHO.
22-Oct-2014 - The head of the US National Institutes of Health has said the organisation would have developed a finished Ebola vaccine by now if its funding had not been slashed over...
21-Oct-2014 - Makers of branded drugs are finding ways to extend their marketing authorisation by patenting not only molecules, but patient screening methods and ways of proving bioequivalence.
|« Previous month||Next month »|